Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Withdrawn 4Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 6Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2Lymphoma, Follicular 2Lymphoma 2Hodgkin Disease 2Ganglioneuroblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Transurethral Resection of Bladder 1Spinal Puncture 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Eflornithine 1Anthropogenic Effects 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Oligodendroglioma × Magnetic Resonance Spectroscopy × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡